Cargando…

Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer

Detalles Bibliográficos
Autores principales:	Kwon, Jennifer, MEAGHER, ALISON
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093347/ https://www.ncbi.nlm.nih.gov/pubmed/25031955

Ejemplares similares

Osimertinib making a breakthrough in lung cancer targeted therapy
por: Zhang, Haijun
Publicado: (2016)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Imatinib: A Breakthrough of Targeted Therapy in Cancer
por: Iqbal, Nida, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Clinical use of crizotinib for the treatment of non-small cell lung cancer
por: Roberts, Patrick J
Publicado: (2013)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
por: D’Angelo, Alberto, et al.
Publicado: (2020)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Wilson, Christabel, et al.
Publicado: (2017)

Crizotinib in the treatment of non-small-cell lung carcinoma
por: Płużański, Adam, et al.
Publicado: (2013)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

Crizotinib targets in glioblastoma stem cells
por: Junca, Audelaure, et al.
Publicado: (2017)

Crizotinib: A comprehensive review
por: Sahu, Arvind, et al.
Publicado: (2013)

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
por: Guo, Liting, et al.
Publicado: (2015)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib
por: Niu, Fei-Yu, et al.
Publicado: (2015)

Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
por: Sosnowska, Bożena, et al.
Publicado: (2022)

Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
por: Xie, Xiaohong, et al.
Publicado: (2019)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
por: Li, Li, et al.
Publicado: (2016)

Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure
por: Hashimoto, Takahiko, et al.
Publicado: (2022)

Genetic polymorphisms in lung disease: bandwagon or breakthrough?
por: Iannuzzi, Michael C, et al.
Publicado: (2002)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
por: Jalil, Ala' A Abdel, et al.
Publicado: (2014)

Role of Crizotinib in previously treated non-small-cell lung cancer
por: Gupta, Sunil Kumar
Publicado: (2014)

Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy
por: Huber, Kilian V. M., et al.
Publicado: (2014)

Cancer Stem Cells: A Potential Breakthrough in HCC-Targeted Therapy
por: Wu, Yafei, et al.
Publicado: (2020)

Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy
por: Katsurada, Naoko, et al.
Publicado: (2019)

PrimPol: A Breakthrough among DNA Replication Enzymes and a Potential New Target for Cancer Therapy
por: Díaz-Talavera, Alberto, et al.
Publicado: (2022)

Crizotinib induces apoptosis of lung cancer cells through JAK-STAT pathway
por: Lu, Hongmin, et al.
Publicado: (2018)

Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Liu, Peng, et al.
Publicado: (2019)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
por: Zhang, Xiangming, et al.
Publicado: (2023)

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2018)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)

Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
por: Guo, Xinyu, et al.
Publicado: (2023)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Renal Injury during Long-Term Crizotinib Therapy
por: Yasuma, Taro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_frkg3abdo5svnft8gccvul83i0